Prevnar 20 vaccine

Phase 3Vaccine

Sanofi

Prevnar 20 vaccine is one of 14 biologic programs targeting Vaccination. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VaccinationActive, not recruiting

VaccinationPhase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Vaccination

#DrugCompanyPhaseTrials

Hepatitis B Vaccine

Sanofi

Phase 3

2 2

Rotarix ™

GSK

Phase 3

6 3

Measles Vaccine

GSK

Phase 3

2 4

PCV21

Sanofi

Phase 3

1 5

Havrix

GSK

Phase 3

1 6

Rotateq

Merck & Co.

Phase 3

2 7

M-M-R II Vaccine

Sanofi

Phase 3

1 8

Vaxelis Vaccine

Sanofi

Phase 3

1 9

Varivax

GSK

Phase 3

1 10

Priorix

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Vaccine

NCT06824194

Phase 3Active, not recruiting

Vaccine

NCT06736041

Q3 2027

Phase 3Active, not recruiting

Vaccination

NCT06824181

Clinical

Trials by Indication[1]

Vaccine2 trials

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT06824194·2,320 enrolled

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06736041·1,714 enrolled

Vaccination1 trial

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT06824181·580 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Prevnar 20 vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prevnar 20 vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prevnar 20 vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Prevnar 20 vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Vaccine2 trials

Vaccination1 trial

References

Drug Info

Quick Facts

Related News